Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Not Applicable

Not yet recruiting

• Conditions: Alzheimer Disease; Mild Cognitive Impairment (MCI); Subjective Cognitive Complaints (SCCs)
• Interventions: Drug: NPC1; Drug: NPC1-Placebo/Control

• Registration Number: NCT07236190
• Lead Sponsor: Massachusetts General Hospital

Brief Summary

The goal of this early phase, open-label, single arm clinical trial is to determine the 6-month effects and tolerability of NPC1 (parthenolide and ipriflavone) on biomarkers of Alzheimer's Disease among adults with objective indicators of seeding AD pathology that also have subjective cognitive concerns, Mild Cognitive Impairment, or Alzheimer's Disease (AD)

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-10
• Study First Submitted: 2025-10-28
• Study First Submitted QC: 2025-11-15
• Last Update Submitted: 2025-11-15
• Study First Posted: 2025-11-19
• Last Update Posted: 2025-11-19
• Study Start: 2025-12-01
• Primary Completion: 2027-06
• Study Completion: 2027-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Age 55 and older, male and female;
2. Subjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011 criteria;
3. Clinical Dementia Rating < or = to 2 and Mini Mental Status Exam > or = to 16;
4. Modified Hachinski Ischemic Score < or = to 4
5. Geriatric Depression Scale - 15 < 6 documenting absence from significant depressive syndromes
6. Other medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable > or = to 3-months ;
7. Biomarker evidence of AD pathology: Plasma abeta42/40 ratio < or = to 0.12 AND Plasma p-tau217 > or = to 0.25 OR Amyloid PET positive (centiloid > or = to 20) as part of routine clinical care.
8. Sufficient vision and hearing to complete all tests
9. Study partner available with frequent (at least 1 hour/day or 1 day/week) contact with participant to provide collateral information about cognition, daily functioning, adverse events reporting, and support for study drug intake
10. General health status that will not interfere with the ability to complete the prospective study (these conditions are listed below in the study exclusion list)

Exclusion Criteria

1. CDR > 2 MMSE < 16;

2. Significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke);

3. Alcohol or substance abuse according to DSM-IV criteria within the last 2 years

4. Major depressive disorder or anxiety within the last year; Schizophrenia, bipolar disorder or other major psychiatric disorder defined by DSM-IV criteria

5. Abnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable)

6. Unstable or significantly symptomatic CVD (e.g. CAD with frequent angina, CHF with dyspnea at rest)

7. Hypertension: defined as uncontrolled BP > 160/100

8. Clinical symptomatic orthostatic hypotension

9. Diabetes mellitus that requires insulin injections

10. Hachinski ischemic score > or = to 4

11. Cancer within the last 5 years, apart from localized prostate cancer (Gleason Grade < 3) and non-metastatic skin cancers (melanoma).

12. Illness that requires >1 visit /month to a clinician

13. Medications and dietary supplements:

    1. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab
    2. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollment is permitted)
    3. CNS active meds that have not been on stable doses for at least 2 months e.g., cimetidine, beta-blockers, and SSRIs
    4. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit
    5. Over the counter supplements are not by themselves exclusionary, however, participants are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these product are recorded

14. Participation in any Alzheimer's Disease interventional trial. Participation in other non-AD related trials will be evaluated at the discretion of the investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open label intervention with NPC1	NPC1	Three capsules of NPC1 taken daily. One 300 mg cap of Ipriflavone and 1 cap of 2.5 mg Parthenolide in the morning; One 300 mg cap of Ipriflavone taken in the evening)
Lead-in observational period	NPC1-Placebo/Control	Serial blood draws to characterize pre-treatment biomarker status

Primary Outcome Measures

Name	Time	Method
Effects on plasma p-tau217	6 months	Changes from baseline intraindividual controlled condition
Effect on plasma GFAP	6 months	Intraindividual changes from baseline
Safety and Tolerability of NPC1	Baseline through 6 months	Assessment of Adverse Events Related to NPC1 Treatment
Effect on plasma abeta42/40	6 months	Intraindividual changes from baseline
Effect on Neurofilament Light Chain (NfL)	6 months	Intraindividual changes from baseline

Secondary Outcome Measures

Name	Time	Method
Effects on plasma hsTNFalpha	6 months	Changes from baseline intraindividual controlled condition

Trial Locations

Locations (1)

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States